Original Article: bit.ly/1DAN1px
UNAIDS welcomes strong indications from two ongoing trials of the effectiveness of antiretroviral therapy in preventing new HIV infections among men who have sex with men.
The IPERGAY trial, conducted by the ANRS, the French National Agency for Research on AIDS and Viral Hepatitis, enrolled 400 men who have sex with men in France to establish the efficacy of taking the antiretroviral combination of tenofovir/emtricitabine as pre-exposure prophylaxis (PrEP) before and after sex rather than daily. The data safety and monitoring board for the IPERGAY trial reviewed data for the study and found a “very significant” reduction in the risk of HIV infection in the group of participants using tenofovir/emtricitabine as PrEP compared to the placebo group. The monitoring board subsequently recommended that the placebo group be stopped and that all trial participants should be offered tenofovir/emtricitabine as PrEP.
This announcement follows a recent decision to amend the PROUD study in the United Kingdom. In the PROUD study, the participants were initially placed at random into two groups—one group that used PrEP from the start of the study and another group that was due to receive PrEP after 12 months. However, the independent data monitoring committee found that the effectiveness seen in the trial exceeded the threshold set for trial continuation and recommended that the researchers offer daily PrEP to all study participants immediately.
Full text of article available at link below: bit.ly/1DAN1px